Inhibikase Kicks Off Global Phase 3 Trial for PAH Drug, Securing Key EU Approvals

WILMINGTON, DE – May 12, 2026 – Clinical-stage pharmaceutical company Inhibikase Therapeutics announced significant progress today in its quest to develop a new treatment for Pulmonary Arterial Hypertension (PAH), a rare and life-threatening disease. Alongside its first-quarter financial results, the company highlighted the enrollment of the first patient in its pivotal Phase 3 study for the drug candidate IKT-001 and the acquisition of critical regulatory approvals across 16 countries.

The global study, named IMPROVE-PAH, has gained considerable momentum by becoming one of the first to leverage the European Medicines Agency's new FAST-EU initiative, a program designed to accelerate multinational clinical trials. This has resulted in approvals to begin the trial in 12 European Union countries, which, combined with clearances in the United States, Canada, New Zealand, and Argentina, provides a broad international foundation for patient recruitment.

“We were excited to enroll the first patient in our registrational IMPROVE-PAH study last month, and are very pleased with our early progress obtaining country regulatory approvals to support initiation of clinical sites,” stated Mark Iwicki, Chief Executive Officer of Inhibikase, in a press release. He noted the company is well-positioned to activate clinical sites globally and advance enrollment, with further data presentations on IKT-001 anticipated at the upcoming American Thoracic Society (ATS) International Conference.

A Second Chance for a Promising Compound

The scientific strategy behind IKT-001 is central to its potential. The drug is a prodrug of imatinib, a well-known tyrosine kinase inhibitor marketed as Gleevec for certain cancers. More than a decade ago, imatinib was studied for PAH in the pivotal IMPRES trial and showed significant efficacy, improving both patient exercise capacity and key hemodynamic measures like pulmonary vascular resistance (PVR).

However, development was halted due to significant tolerability issues. The oral form of imatinib caused severe side effects, including nausea, edema, and rashes, leading to a high rate of patients discontinuing treatment. The IMPRES study reported that 33% of patients on imatinib dropped out, compared to 18% on placebo.

Inhibikase aims to solve this problem with IKT-001. As a prodrug, it is an inactive molecule when ingested, designed to be absorbed and then converted by the body into active imatinib. This approach is intended to bypass the gastrointestinal issues that plagued the original drug, potentially offering the same anti-proliferative benefits with a much-improved safety and tolerability profile. The challenge of using imatinib in PAH was recently underscored by the June 2024 failure of Aerovate Therapeutics' inhaled version, AV-101, which did not meet its primary endpoint in a Phase 2b study, demonstrating that the delivery and formulation of the compound are critical hurdles.

In recognition of the high unmet need for new PAH therapies, which affects an estimated 50,000 people in the U.S., Inhibikase also submitted an Orphan Drug Designation application to the FDA for IKT-001 in April.

A Sophisticated and Adaptive Trial Design

The IMPROVE-PAH study (NCT07365332) is structured as a two-part, adaptive Phase 3 trial, reflecting a modern approach to drug development designed for efficiency and patient-centricity. The trial begins with a 12-week dose titration phase, allowing clinicians to find the highest tolerable dose for each individual patient before the primary evaluation period.

Part A of the study will enroll approximately 140 patients, with the primary goal of measuring the change in Pulmonary Vascular Resistance (PVR) at 24 weeks. This hemodynamic measure is a direct indicator of pressure in the lung's arteries.

Following the enrollment of the last patient in Part A, the study will seamlessly transition into Part B. This larger portion will enroll about 346 patients and use an identical study format, but its primary endpoint will shift to the change in the 6-minute walk distance (6MWD) at 24 weeks—a key functional measure of exercise capacity and quality of life for PAH patients. This adaptive design provides flexibility, allowing for a potential sample size re-estimation for Part B based on the findings from Part A, if necessary.

Balancing Clinical Ambition with Financial Reality

Running a global Phase 3 trial across approximately 180 sites is a significant financial undertaking. Inhibikase's first-quarter financial report provides a snapshot of a company in the throes of this critical, cash-intensive phase. The company reported a strong cash, cash equivalents, and marketable securities position of $170.4 million as of March 31, 2026, providing a substantial runway to fund its ongoing operations.

However, the costs of advancing the program are evident. The company reported a net loss of $16.4 million for the quarter, an increase from the $13.7 million loss in the same period last year. Research and development (R&D) expenses held steady at $10.8 million, while selling, general, and administrative (SG&A) expenses rose to $7.4 million from $5.2 million in the prior-year quarter, reflecting the ramp-up in global trial activities.

These figures are typical for a clinical-stage biotech and underscore the high-stakes nature of late-stage drug development. The company's robust cash position is a critical asset, but investors will be closely monitoring the burn rate as patient enrollment scales up worldwide. The next key inflection point for the company will be the presentation of its Phase 1 and preclinical data at the ATS conference later this week, which will offer the scientific community its first detailed look at the data supporting IKT-001's potential to succeed where its predecessor fell short.